Lapatinib (Figure 2), a synthetic quinazoline derivative, is an orally active reversible ErbB1 and ErbB2 tyrosine kinase receptor inhibitor that possesses antineoplastic activity towards breast cancer [39]. The gene discussed is ERBB2; the disease is breast cancer.